Jessica A. Sorrentino,Jay Copeland Strum,John E. Bisi,Andrew Beelen
申请号：
US16547342
公开号：
US20190374545A1
申请日:
2019.08.21
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present invention provides methods for treating a EGFR-mutant cancer in a patient by administering a selective CDK4/6 inhibitor described herein in combination or alternation with an EGFR-TKI to delay or reverse acquired resistance to previously administered EGFR-TKIs. In addition, methods for treating a EGFR-mutant cancer in a patient by administering a selective CDK4/6 inhibitor described herein in combination or alternation with an EGFR-TKI are provided wherein an intrinsically EGFR-TKI resistant EGFR-mutant cancer is sensitized to the effects of the EGFR-TKI.
